Immix Net Interest Income from 2010 to 2024

IMMX Stock  USD 1.72  0.07  3.91%   
Immix Biopharma Net Interest Income yearly trend continues to be fairly stable with very little volatility. Net Interest Income is likely to outpace its year average in 2024. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2010-12-31
Previous Quarter
343.4 K
Current Value
360.6 K
Quarterly Volatility
165 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 360.6 K or Depreciation And Amortization of 3 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.68 or Book Value Per Share of 0.98. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Latest Immix Biopharma's Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of Immix Biopharma over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Immix Biopharma's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

Immix Net Interest Income Regression Statistics

Arithmetic Mean(45,209)
Coefficient Of Variation(364.92)
Mean Deviation111,888
Median(109,984)
Standard Deviation164,975
Sample Variance27.2B
Range540.5K
R-Value0.61
Mean Square Error18.4B
R-Squared0.37
Significance0.02
Slope22,524
Total Sum of Squares381B

Immix Net Interest Income History

2024360.6 K
2023343.4 K
2022 -497.0
2021-179.9 K
2020-102 K

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Interest Income343.4 K360.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.